1326232-46-5
1326232-46-5 structure
- Name: Anifrolumab
- Chemical Name: Anifrolumab
- CAS Number: 1326232-46-5
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Inflammation/Immunology
- Create Date: 2022-10-23 17:43:47
- Modify Date: 2025-08-25 11:01:30
-
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research[1][2].
| Name | Anifrolumab |
|---|
| Description | Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Anifrolumab (67.7 nM; 20 min) induces sustained reduction of surface IFNAR1 and abrogates STAT1 phosphorylation[2]. Anifrolumab (1 and 10 μg/mL; 6 or 7 d) suppresses differentiation of B cells into plasma cells[2]. Anifrolumab inhibits type I IFN-induced ISRE signaling, with IC50s ranging from 0.004 to 0.3 nM for the IFN-α subtypes, and 0.03 nM and 0.07 nM for IFN-β and IFN-ω, respectively[2]. Anifrolumab (67.7 nM) dose-dependently inhibits IFN-α production from pDCs in response to CpG-A or DNA-IC stimulation, inhibiting 87-95% of IFN-α production[2]. Western Blot Analysis[2] Cell Line: Peripheral blood mononuclear cells (PBMCs) Concentration: 67.7 nM Incubation Time: 20 min Result: Abrogated IFN-α2-dependent and pDC supernatant-dependent STAT1 phosphorylation. Cell Differentiation Assay[2] Cell Line: Plasmacytoid dendritic cell (pDC) Concentration: 1 and 10 μg/mL Incubation Time: 6 or 7 days Result: Inhibited pDC-mediated plasma cell differentiation in a dose-dependent manner, with a mean 76% reduction in plasma cell number relative to control antibody. |
| References |
| No Any Chemical & Physical Properties |